Sign In
Buy ZVRA
$13.00
+0.350 (+2.77%)
At Close: Jun 23, 2026
Zevra Therapeutics to Report Second Quarter 2024 Financial Results
08:38am, Tuesday, 30'th Jul 2024
CELEBRATION, Fla., July 30, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company) a rare disease therapeutics company, today announced that it will host a conferen
Zevra (ZVRA) Rises on Update on Niemann-Pick Disease Type C Drug
04:06pm, Wednesday, 10'th Jul 2024
The FDA will meet with its Genetic Metabolic Diseases Advisory Committee to review Zevra's (ZVRA) new drug application for pipeline candidate arimoclomol. Shares of Zevra gains on the news.
Zevra Therapeutics (ZVRA) Surges 21.9%: Is This an Indication of Further Gains?
09:25am, Wednesday, 10'th Jul 2024
Zevra Therapeutics (ZVRA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the nea
CELEBRATION, Fla. and ELK GROVE VILLAGE, Ill., June 18, 2024 (GLOBE NEWSWIRE) -- Orsini Specialty Pharmacy (Orsini), and Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra) today announced that Orsini i
KP1077 was well tolerated and showed meaningful clinical improvements in patient-reported assessments of daytime sleepiness, sleep inertia, and brain fog
Zevra Therapeutics, Inc. (ZVRA) Q1 2024 Earnings Call Transcript
02:53pm, Wednesday, 08'th May 2024
Zevra Therapeutics, Inc. (NASDAQ:ZVRA ) Q1 2024 Earnings Conference Call May 8, 2024 8:00 AM ET Company Participants Nichol Ochsner - VP, Investor Relations & Corporate Communications Neil Mcfarlane -
Zevra Therapeutics (ZVRA) Reports Q1 Loss, Lags Revenue Estimates
09:16am, Wednesday, 08'th May 2024
Zevra Therapeutics (ZVRA) came out with a quarterly loss of $0.40 per share versus the Zacks Consensus Estimate of a loss of $0.49. This compares to loss of $0.34 per share a year ago.
Zevra Therapeutics Reports First Quarter 2024 Financial Results and Corporate Updates
07:00am, Wednesday, 08'th May 2024
Full commercial launch of OLPRUVA at the end of January 2024, with market access growing to ~ 75% of covered lives as of May 1, 2024
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zevra Therapeutics, Inc. - ZVRA
07:49pm, Monday, 06'th May 2024
NEW YORK , May 6, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Zevra Therapeutics, Inc. ("Zevra" or the "Company") (NASDAQ: ZVRA). Such investors are advised
Zevra Therapeutics to Report First Quarter 2024 Results on May 8, 2024
07:30am, Wednesday, 01'st May 2024
CELEBRATION, Fla., May 01, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a rare disease therapeutics company, today announced that it will host a conferen
CELEBRATION, Fla., April 29, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a rare disease therapeutics company, today announced that Neil F. McFarlane, Ze
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zevra Therapeutics, Inc. - ZVRA
09:45am, Sunday, 28'th Apr 2024
NEW YORK , April 28, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Zevra Therapeutics, Inc. ("Zevra" or the "Company") (NASDAQ: ZVRA). Such investors are advis
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zevra Therapeutics, Inc. - ZVRA
12:00pm, Saturday, 20'th Apr 2024
NEW YORK , April 20, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Zevra Therapeutics, Inc. ("Zevra" or the "Company") (NASDAQ: ZVRA). Such investors are advis
The oral presentation highlighted data from Zevra's Expanded Access Program demonstrating a consistent safety profile
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zevra Therapeutics, Inc. - ZVRA
09:30am, Friday, 12'th Apr 2024
NEW YORK , April 12, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Zevra Therapeutics, Inc. ("Zevra" or the "Company") (NASDAQ: ZVRA). Such investors are advised
